Press Releases
Studies / Reports
Media Inquiries / Spokespeople
BizVoice Magazine
Multimedia

Membership
Join Now!

FEATURED PRODUCTS

Health Care Savings
Employment Posters
Office Solutions

Drug Formulary Bill for Workers Comp. Heard in Committee; Opioid Continuing Education Bill Passes Full Senate

2018-01-26T14:27:56+00:00 January 26th, 2018|

Drug Formulary Bill for Workers Comp. Heard in Committee

Bill and Title: SB 369 – Workers Compensation Drug Formulary
Author: Sen.  Randy Head (R-Logansport)
Summary: Requires the commissioner of insurance to adopt rules for exclusive use, beginning July 1, 2020, of a workers’ compensation drug formulary by workers’ compensation insurers. Specifies application of the formulary for employees who file notice of injury or occupational disease before July 1, 2019.
Chamber Position: Support
Status: Heard in the Senate Pensions and Labor Committee, but no vote was taken – awaiting amendments and further work.

Update/Chamber Action: The Chamber testified that drug formularies have been adopted in health insurance markets, Medicaid and Medicare for years. Plus, creating formularies for workers compensation is a growing trend. Texas created a drug formulary in 2011 and its data revealed significant cost savings in prescription drugs and opioids. Thus, two benefits come from the legislation: addressing cost savings for workers comp and decreasing the supply of opioids by reducing prescriptions.

The Insurance Institute of Indiana testified in favor by providing physician expertise on the operation of formularies and how this would work in workers compensation. Additionally, the Indiana Manufacturers Association (IMA) provided testimony on the workers compensation system and the benefits that could be derived from a formulary. Meanwhile, organized labor opposed the bill, stating its belief that there isn’t an opioid problem involving workers compensation while listing various other problems with the bill.

Along with Sen. Head, the Indiana Chamber, Insurance Institute, IMA, the Worker’s Compensation Board and the Indiana State Medical Association are attempting to draft a workable solution to the bill – in order for a vote to be taken next week.

Opioid Continuing Education Bill Passes Full Senate

Bill # and Title: SB 225 – Continuing Education Requirements
Author: Sen. Randy Head (R-Logansport)
Summary: Establishes continuing education requirements for licensed health care practitioners who apply for a controlled substances registration. Provides that the continuing education requirements expire July 1, 2025.
Chamber Position: Support
Status: The bill passed the Senate 49-0.

Update/Chamber Action: The Chamber supports measures that reduce the supply of opioids and communicated as such. This bill educates providers that have a CSR (controlled substance registration) and as a result, could reduce the number of opioid prescriptions and potentially decrease the overall supply of controlled substances.

Resource: Mike Ripley at (317) 264-6883 or e-mail: mripley@indianachamber.com